Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format, (APPEL5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03858062
Recruitment Status : Completed
First Posted : February 28, 2019
Last Update Posted : October 22, 2019
Sponsor:
Collaborators:
Rijnstate Hospital
Inreda Diabetic
Information provided by (Responsible Party):
J.H. DeVries, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary:
In previous studies, the investigators tested the feasibility of a bi-hormonal reactive closed loop system without mealtime announcement. This system for automated control of blood glucose in patients with type 1 diabetes was tested in the clinical research center (APPEL 1 and 2) as well as at the home of the patients (APPEL 3 and 4). After the APPEL 4 study some improvements have been made to the miniaturized prototype to allow patients to operate the system independently and additional risk control measures were included. The main objective of this study is to assess the efficacy of this improved closed loop system.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Device: Insulin pump therapy (with or without glucose sensor) Device: Artificial pancreas (Inreda Diabetic) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format, APPEL 5
Actual Study Start Date : March 10, 2019
Actual Primary Completion Date : September 12, 2019
Actual Study Completion Date : September 12, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Active Comparator: Open loop
14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
Device: Insulin pump therapy (with or without glucose sensor)
Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
Other Names:
  • Continuous subcutaneous insulin infusion (CSII)
  • Sensor augmented pump therapy (SAP)

Experimental: Closed loop
4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
Device: Artificial pancreas (Inreda Diabetic)
Bi-hormonal reactive closed loop system without mealtime announcement
Other Name: Closed loop therapy




Primary Outcome Measures :
  1. Time in target [ Time Frame: Week 1-2 ]
    Proportion of time spent in the target range (3.9-10 mmol/l)


Secondary Outcome Measures :
  1. Time in hypoglycemia 1 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Proportion of time spent in hypoglycemia (<3.9 mmol/l)

  2. Time in hypoglycemia 2 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Proportion of time spent in hypoglycemia (<3.3 mmol/l)

  3. Time in hyperglycemia 1 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Proportion of time spent in hyperglycemia (>10 mmol/l)

  4. Time in hyperglycemia 2 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Proportion of time spent in hyperglycemia (>13.9 mmol/l)

  5. Hypoglycemic events [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Number of carbohydrate-treated hypoglycemic events

  6. Mean or median glucose [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Mean or median sensor glucose concentration

  7. Mean or median day glucose [ Time Frame: Day time: Week 1-2 / Week 1 / Week 2 ]
    Mean or median sensor glucose concentration

  8. Mean or median night glucose [ Time Frame: Night time: Week 1-2 / Week 1 / Week 2 ]
    Mean or median sensor glucose concentration

  9. Mean or median postprandial glucose [ Time Frame: Postprandial: Week 1-2 / Week 1 / Week 2 ]
    Mean or median sensor glucose concentration

  10. Glycemic variability 1 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Interquartile range (IQR)

  11. Glycemic variability 2 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Coefficient of variation (CV)

  12. Glycemic variability 3 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Low blood glucose index (LBGI)

  13. Glycemic variability 4 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    High blood glucose index (HBGI)

  14. Glycemic variability 5 [ Time Frame: Week 1-2 / Week 1 / Week 2 ]
    Blood glucose risk index (BGRI)

  15. Time in target [ Time Frame: Week 1 / Week 2 ]
    Proportion of time spent in the target range (3.9-10 mmol/l)

  16. PAID: Problem Areas In Diabetes questionnaire [ Time Frame: Baseline / End week 2 ]
    Total score; Scale 0 (no problems) to 80 (big problems)

  17. EQ5D: EuroQol 5 Dimensions questionnaire [ Time Frame: Baseline / End week 2 ]
    Quality of life measure; Scale 1 ("no problem) to 5 ("extreme problems")

  18. DTSQ-status: Diabetes Treatment Satisfaction Questionnaire [ Time Frame: Baseline / End week 2 ]
    Total score: Scale 0 (negative) to 36 (positive)

  19. DTSQ-change: Diabetes Treatment Satisfaction Questionnaire [ Time Frame: End week 2 ]
    Change in DTSQ; Total score: Scale -18 (negative) to 18 (positive)

  20. Algorithm active time [ Time Frame: Week 1-2 (closed loop only) ]
    Percentage of time that the closed loop algorithm is active

  21. Usability score [ Time Frame: End week 2 (closed loop only) ]
    Questionnaire: Mobile Phone Usability Questionnaire (MPUQ); Total score: Scale 62 (low level of usability) to 310 (higher level of usability)

  22. Glucose measurement performance [ Time Frame: Day 3, 4 or 5 of the training period prior to the closed loop ]
    MARD


Other Outcome Measures:
  1. Demographic variables [ Time Frame: Baseline ]
  2. Weight [ Time Frame: Baseline ]
  3. Length [ Time Frame: Baseline ]
  4. HbA1c plasma concentration [ Time Frame: Baseline ]
  5. Meals [ Time Frame: Week 1-2 ]
    Carbohydrate intake

  6. Physical activity 1 [ Time Frame: Week 1-2 ]

    Number of exercise moments per intensity category ("light", "moderate", "heavy'"

    )


  7. Physical activity 2 [ Time Frame: Week 1-2 ]

    Duration of exercise moments per intensity category ("light", "moderate", "heavy'"

    )


  8. Physical activity 3 [ Time Frame: Week 1-2 ]
    Total number of exercise moments

  9. Physical activity 4 [ Time Frame: Week 1-2 ]
    Total duration of exercise moments

  10. Insulin dose [ Time Frame: Week 1-2 ]
    Daily average

  11. Glucagon dose [ Time Frame: Week 1-2 ]
    Daily average



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with diabetes mellitus type 1;
  • Treated with SAP or CSII for a minimum of 6 months;
  • Willing and able to sign informed consent.

Exclusion Criteria:

  • Impaired awareness of hypoglycemia (score ≥ 4) according to Gold and/or Clarke questionnaire;
  • BMI > 35 kg/m2;
  • HbA1c > 97 mmol/mol (=11.0 %);
  • Use of heparin, coumarin derivatives or oral corticosteroids;
  • Use of acetaminophen during the open loop or closed loop period, as this may influence the sensor glucose measurements;
  • Limited ability to see, and to hear or feel alarm signals of the closed loop system;
  • Skin condition prohibiting needle insertion;
  • Pregnancy and/or breastfeeding;
  • Living alone during the night during the closed loop period (the patient may ask someone to stay over temporarily);
  • Expected poor connectivity with internet regarding 24/7 tele monitoring;
  • Any condition that the local investigator feels would have interfere with trial participation or the evaluation of the results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03858062


Locations
Layout table for location information
Netherlands
Rijnstate Hospital
Arnhem, Gelderland, Netherlands, 6815 AD
Academic Medical Center
Amsterdam, Noord-Holland, Netherlands, 1105 AZ
Sponsors and Collaborators
J.H. DeVries
Rijnstate Hospital
Inreda Diabetic
Investigators
Layout table for investigator information
Principal Investigator: J.H. DeVries, MD PhD Academisch Medisch Centrum, Universiteit van Amsterdam

Publications:
Layout table for additonal information
Responsible Party: J.H. DeVries, Endocrinologist, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT03858062     History of Changes
Other Study ID Numbers: NL55693.018.15
First Posted: February 28, 2019    Key Record Dates
Last Update Posted: October 22, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by J.H. DeVries, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Artificial pancreas
Glucose control
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Pancrelipase
Pancreatin
Hypoglycemic Agents
Physiological Effects of Drugs
Gastrointestinal Agents